Company / R&D Expense
Compass Therapeutics, Inc. R&D Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$42.3M
FY2024
5-year range
$14.9M / $42.3M
FY2020-FY2024
Trend
+11.1%
vs FY2023
Sector context
#182 of 210
Health Care
What the data says
Compass Therapeutics, Inc.'s r&d expense of $42M is lower than 87% of companies in the Health Care sector (FY2024). R&D Expense has increased for 4 consecutive years, from $15M in FY2020 to $42M in FY2024.
Based on SEC 10-K filings.
$42M in FY2024 with a 5-year CAGR of +13.5%.
Improved from $30M to $42M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +27.7%
- 5-Year CAGR
- +13.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 210This company $42.3M Sector average $644.1M
▼
-93.4% below sector average
Key checks
Key Insights
- Compass Therapeutics, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +13.5%, indicating consistent growth.
- In FY2024, r&d expense increased 11.1% year-over-year.
- Ranks #182 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $42.3M | +11.1% |
| FY2023 | $38.1M | +27.1% |
| FY2022 | $30.0M | +47.5% |
| FY2021 | $20.3M | +36.5% |
| FY2020 | $14.9M | -33.6% |
| FY2019 | $22.4M | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026